$0.61
6.10% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US2666051048
Symbol
DRRX
Sector
Industry

DURECT Corporation Stock price

$0.61
-0.13 17.35% 1M
-0.29 32.48% 6M
-0.14 18.65% YTD
-0.43 41.34% 1Y
-3.36 84.62% 3Y
-24.49 97.57% 5Y
-23.29 97.45% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.04 6.10%
ISIN
US2666051048
Symbol
DRRX
Sector
Industry

Key metrics

Market capitalization $18.94m
Enterprise Value $12.66m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.60
P/S ratio (TTM) P/S ratio 3.89
P/B ratio (TTM) P/B ratio 3.54
Revenue growth (TTM) Revenue growth -41.45%
Revenue (TTM) Revenue $4.87m
EBIT (operating result TTM) EBIT $-14.93m
Free Cash Flow (TTM) Free Cash Flow $-15.87m
Cash position $8.26m
EPS (TTM) EPS $-0.51
P/E forward negative
P/S forward 28.54
EV/Sales forward 19.08
Short interest 2.32%
Show more

Is DURECT Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

DURECT Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a DURECT Corporation forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a DURECT Corporation forecast:

Buy
67%
Hold
33%

Financial data from DURECT Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
4.87 4.87
41% 41%
100%
- Direct Costs 0.96 0.96
41% 41%
20%
4.01 4.01
42% 42%
82%
- Selling and Administrative Expenses 11 11
20% 20%
220%
- Research and Development Expense 8.15 8.15
67% 67%
167%
-15 -15
53% 53%
-305%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -15 -15
53% 53%
-306%
Net Profit -16 -16
32% 32%
-327%

In millions USD.

Don't miss a Thing! We will send you all news about DURECT Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

DURECT Corporation Stock News

Neutral
PRNewsWire
7 days ago
Planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH) with topline results expected within two years of trial initiation Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 CUPERTINO, Calif. , May 13, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the first quarter ended Mar...
Neutral
Seeking Alpha
about 2 months ago
DURECT Corporation (NASDAQ:DRRX ) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Co-Founder, Chief Executive Officer, President, Director Norman Sussman - Chief Medical Officer WeiQi Lin - Executive Vice President, Research & Development and Principal Scientist Conference Call Participants François Brisebois - Oppen...
Neutral
PRNewsWire
about 2 months ago
Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif.
More DURECT Corporation News

Company Profile

DURECT Corp. is a biopharmaceutical company. It engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

Head office United States
CEO James Brown
Employees 31
Founded 1998
Website www.durect.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today